hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06353152, orgStudyIdInfo id: GC506-507, briefTitle: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-17, primaryCompletionDateStruct date: 2025-11-16, completionDateStruct date: 2025-11-16, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Peking University, class: OTHER, collaborators name: Gracell Biopharmaceuticals, Inc., descriptionModule briefSummary: A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma., conditionsModule conditions: Gastric Adenocarcinoma, conditions: Gastroesophageal Junction Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection, outcomesModule primaryOutcomes measure: Occurrence of Dose limiting toxicity., primaryOutcomes measure: Incidence of treatment-emergent AEs, AESIs, and SAEs., secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Duration of disease control (DDC), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Proliferation and persistence of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell, secondaryOutcomes measure: Incidence of anti-CAR-T cell antibody in peripheral blood after infusion., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Cancer Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100142, country: China, contacts name: Shen Lin, Professor, role: CONTACT, phone: 010-88196561, email: doctorshenlin@sina.cn, contacts name: Shen Lin, professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06353139, orgStudyIdInfo id: 90591, briefTitle: The Efficacy of Modified Olfactory Training for Patients With Olfactory Dysfunction, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are:Is it possible that the device can treat olfactory disorders in adults? Compared to the conventional device, how efficient is the modified olfactory training device for treating patients with olfactory disfunction?, conditionsModule conditions: Olfactory Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: Modified olfactory training device, outcomesModule primaryOutcomes measure: Clinically significant olfactory improvement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dawei Wu, status: RECRUITING, city: Beijing, state: Beijing, zip: 100191, country: China, contacts name: Dawei Wu, MD, PhD, role: CONTACT, phone: 13522503401, email: davidwuorl@163.com, contacts role: CONTACT, phoneExt: Wu, email: davidwuorl@163.com, contacts name: Dawei Wu, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06353126, orgStudyIdInfo id: DTACESALT, briefTitle: DEB-TACE Prior to Liver Transplantation in the Treatment of HCC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2027-07-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, collaborators name: Boston Scientific Corporation, descriptionModule briefSummary: The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to SALT (Sequential Adult Left Lateral Liver Transplantation) can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for SALT receive DEB-TACE 2 weeks prior to the surgery.The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing SALT; 4) Adverse events related to DEB-TACE., conditionsModule conditions: Liver Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: DEB-TACE, outcomesModule primaryOutcomes measure: Recurrence-free survival (RFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Pathological response rate (Pathological Response), secondaryOutcomes measure: Proportion of patients completing SALT, secondaryOutcomes measure: Adverse events related to DEB-TACE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353100, orgStudyIdInfo id: 230602006, briefTitle: Chronic Pain in the General Population of Chile, acronym: RDC, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Pontificia Universidad Catolica de Chile, class: OTHER, collaborators name: Chilean Safety Association (ACHS), descriptionModule briefSummary: The present study seeks to follow up the cohort of adults representative of Chile's urban population whose levels of chronic pain were evaluated in March 2023 (baseline) as part of the Mental Health Thermometer (MHT) study. The study consists of a 12 month follow-up telephone interview to assess parameters of chronic pain (CP) and subtypes, mental and physical health, lifestyle and adversity and work characteristics.The study objectives are as follows:1. Estimate the prevalence of CP and subtypes in the general population2. Explore the association between mental health indicators, perceived work stress and presence of CP in the population.3. Investigate the impact of CP (functional, occupational and social) among the subset of participants reporting CP4. Describe the use of management strategies in those who suffer from CP., conditionsModule conditions: Chronic Pain, conditions: Migraine Disability, conditions: Neuropathic Pain, conditions: Fibromyalgia, conditions: Depression, Anxiety, conditions: Self Harm, conditions: Insomnia, conditions: Loneliness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 2365, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Chronic pain (past 3 months), primaryOutcomes measure: Depression (2 weeks), primaryOutcomes measure: Anxiety (2 weeks), secondaryOutcomes measure: Migraine Disability, secondaryOutcomes measure: Neuropathic Pain, secondaryOutcomes measure: Fibromyalgia, secondaryOutcomes measure: Self harm (2 weeks), secondaryOutcomes measure: Insomnia (2 weeks), secondaryOutcomes measure: Loneliness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pontificia Universidad Catolica de Chile, city: Santiago, state: RM, zip: 7550139, country: Chile, geoPoint lat: -33.45694, lon: -70.64827, hasResults: False
protocolSection identificationModule nctId: NCT06353074, orgStudyIdInfo id: 1335cemre., briefTitle: Uterine Preservation With Acar's Atony Suture for Postpartum Uterine Hemorrhage, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2023-11-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Necmettin Erbakan University, class: OTHER, descriptionModule briefSummary: This study is aimed to show effectiveness of a new suture technique to stop postpartum uterine bleeding due to uterine atony., conditionsModule conditions: Uterine Atony With Hemorrhage, conditions: Postpartum Hemorrhage, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 16, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Postpartum hysterectomy and/or intensive care unit need ratio, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cemre Alan, city: Konya, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06353061, orgStudyIdInfo id: LACC-MET, briefTitle: Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2026-02-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: This is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and further improve progression-free survival. The study aims to compare the improvement of tumor hypoxia with synchronous chemoradiotherapy with or without metformin, using CA-IX PET/CT and radiation positioning spectral CT to evaluate tumor hypoxia, screening hypoxic patients for inclusion in the study, and comparing the effects of synchronous chemoradiotherapy with or without metformin on the degree of hypoxia and progression-free survival in the two groups of patients., conditionsModule conditions: Cervical Cancer, conditions: Radiotherapy, conditions: Metformin, conditions: Hypoxia, conditions: PET/CT, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 51, type: ESTIMATED, armsInterventionsModule interventions name: Metformin, interventions name: Radiotherapy, interventions name: Chemotherapy, interventions name: PET/CT, outcomesModule primaryOutcomes measure: The degree to which metformin improves the hypoxic index measured by CAIX PET, secondaryOutcomes measure: Progression-free survival（PFS）, secondaryOutcomes measure: Changes in tumor volume during treatment, secondaryOutcomes measure: Hematologic and gastrointestinal toxicities assessed by CTCAE v5.0, secondaryOutcomes measure: Quality of life assessed by QLQ-C30, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353009, orgStudyIdInfo id: ICM 2021-2720, briefTitle: Effect of a Single Ultra-Processed Meal on Myocardial Endothelial Function Assessed With Positron Emission Tomography, acronym: SUPPER, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-08-20, primaryCompletionDateStruct date: 2023-04-28, completionDateStruct date: 2023-04-28, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Matthieu Pelletier-Galarneau, MD MSc, class: OTHER, descriptionModule briefSummary: The objective of this study is to evaluate the effect of an ultra-processed meal on myocardial endothelial function using positron emission tomography (PET).The proposed study is an open-label, randomized crossover clinical trial. Participants will be divided into 2 groups: half of the participants will consume a Mediterranean meal during the first experimental visit and an ultra-processed meal during the second, and vice versa for the other half. The order in which the meals will be consumed will be determined randomly.This project will contribute to clarify the role of diet in the development and progression of coronary artery disease. The results obtained from this study may potentially demonstrate the harmful effect of ultra-processed foods, even in the short term, on coronary arteries., conditionsModule conditions: Myocardial Endothelial Function, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule interventions name: NOVA4 meal, interventions name: NOVA1-3 meal, outcomesModule primaryOutcomes measure: Myocardial blood flow values (ml/min/g) at maximum dose of adenosine., secondaryOutcomes measure: Myocardial blood flow values (ml/min/g) at rest and myocardial reserve., secondaryOutcomes measure: Myocardial blood flow values (ml/min/g) at intermediate dose of adenosine., eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Matthieu Pelletier-Galarneau, city: Montreal, state: Quebec, zip: H1T 1C8, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06352996, orgStudyIdInfo id: Dentist Anas Kassas, briefTitle: Three-Dimensional Assessment of Maxillary Canine Retraction With and Without Power Arm, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-06-09, primaryCompletionDateStruct date: 2024-03-09, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: Aim of the study: This trial will be conducted for three-dimensional assessment of canine retraction with and without power arm.Materials and methods:Twenty patients with age range between 14 to 25 years. Before bonding, a hook will be attached to the canine bracket in one side only. Leveling and alignment then The first premolars will be extracted and mini-implant will be inserted.Canine retraction using nickel titanium closed coil spring will start in the same day of upper first premolar extraction., conditionsModule conditions: Power Arm Canine Retraction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm, interventions name: Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm, outcomesModule primaryOutcomes measure: Canine tipping, primaryOutcomes measure: Canine mobility, primaryOutcomes measure: Implant stability, primaryOutcomes measure: Pain assessment, primaryOutcomes measure: canine rotation, primaryOutcomes measure: canine retraction rate, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of dentistry Mansoura University, city: Mansoura, country: Egypt, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06352983, orgStudyIdInfo id: 2014/11, briefTitle: Zirconium Dioxide Fixed Dental Prosthesis., statusModule overallStatus: COMPLETED, startDateStruct date: 2017-12-20, primaryCompletionDateStruct date: 2019-09-27, completionDateStruct date: 2023-01-20, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Malmö University, class: OTHER, descriptionModule briefSummary: The purpose of this clinical trial is to evaluate and compare bridges to replace one or two missing teeth in the mouth. The bridges will be made of two variants of ceramic material. We will evaluate the bridges for up to five years regarding technical and biological complications., conditionsModule conditions: Missing Teeth, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled trial, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Both participant, care providers, dental technicians and the investigator are blinded in the process., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 31, type: ACTUAL, armsInterventionsModule interventions name: Fixed dental prosthesis, outcomesModule primaryOutcomes measure: Fractures, primaryOutcomes measure: De-bonding, secondaryOutcomes measure: Caries, secondaryOutcomes measure: Endodontic, secondaryOutcomes measure: Function, secondaryOutcomes measure: Esthetics, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Malmo university, city: Malmo, state: Skane, zip: 214 21, country: Sweden, geoPoint lat: 55.60587, lon: 13.00073, locations facility: Malmo university, city: Malmo, state: Skane, zip: 21421, country: Sweden, geoPoint lat: 55.60587, lon: 13.00073, hasResults: False
protocolSection identificationModule nctId: NCT06352970, orgStudyIdInfo id: LundU-2024, briefTitle: Effects of Tuberculosis Infection on Development and Function of the Placenta, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Lund University, class: OTHER, collaborators name: Addis Ababa University, collaborators name: Armauer Hansen Research Institute, Ethiopia, descriptionModule briefSummary: The goal of this observational study is to understand how tuberculosis (TB) infection impacts the function and development of the placenta, and whether TB infection can contribute to pregnancy-related disorders through effects on the placenta.The main questions it aims to answer are:* Does TB infection affect the structure of the placenta?* Does TB infection affect the function of the placenta?Pregnant women attending delivery clinics in Addis Abeba, Ethiopia, will be enrolled and classified for TB infection using a blood-based test. We will compare the following outcomes between women with TB infection and women without TB infection:* Pathological lesions of the placenta* Gene and protein expression patterns linked to pregnancy-related disorders* Infant outcome at birth and at 6 weeks after birth, conditionsModule conditions: Pregnancy Related, conditions: Tuberculosis Infection, conditions: Placenta Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: TB infection, outcomesModule primaryOutcomes measure: Proportion of women with pathological placental findings according to the Amsterdam consensus criteria, secondaryOutcomes measure: Proportions of women with placental RNA and protein expression patterns linked to pregnancy- related disorders, secondaryOutcomes measure: Proportions of infants (born to participating women) with adverse outcome, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352944, orgStudyIdInfo id: AssiutMD, briefTitle: Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity ), conditionsModule conditions: Non-cystic Fibrosis Bronchiectasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: procalcitonin, outcomesModule primaryOutcomes measure: procalcitonin level in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352931, orgStudyIdInfo id: TCD & TCUS in infants, briefTitle: Transcranial Ultrasound and Transcranial Doppler in Diagnosis and Detection of Outcome in Infants With Neurological Diseases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-07-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: To evaluate the accuracy of transcranial ultrasound in detection of brain pathology in infants with neurological diseases and value of transcranial Doppler in evaluation of intracerebral blood flow in comparison with other radiological modalities according to available imaging., conditionsModule conditions: Trancranial Doppler, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: transcranial and transcranial dopp;er, outcomesModule primaryOutcomes measure: To evaluate the accuracy of transcranial ultrasound in detection of brain pathology in infants with neurological diseases and value of transcranial doppler, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 1 Year, stdAges: CHILD, contactsLocationsModule, hasResults: False